|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 37.88 USD | -4.27% |
|
-11.23% | -23.78% |
| 09-17 | Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger | MT |
| 08-03 | Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2026 | CI |
Company Valuation: Supernus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,551 | 1,928 | 1,581 | 1,997 | 2,850 | 2,202 | - | - |
| Change | - | 24.34% | -18% | 26.29% | 42.72% | -22.74% | - | - |
| Enterprise Value (EV) | 1,551 | 1,928 | 1,581 | 1,997 | 2,850 | 2,202 | 2,202 | 2,202 |
| Change | - | 24.34% | -18% | 26.29% | 42.72% | -22.74% | 0% | 0% |
| P/E | 29.8x | 34.3x | 1,447x | 27.4x | -73.1x | -165x | 33.7x | 17.6x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 5.6x | -14.8x | 0x | 0x | 2.5x | -0x | 0.2x |
| Capitalization / Revenue | 2.67x | 2.89x | 2.6x | 3.02x | 3.96x | 2.49x | 1.61x | 1.32x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.49x | 1.61x | 1.32x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 13x | 2.84x | 2.45x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 18.6x | 10.8x | 6.38x |
| FCF Yield | 8.07% | 6.04% | 6.99% | 8.58% | 1.61% | 5.39% | 9.23% | 15.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.98 | 1.04 | 0.02 | 1.32 | -0.68 | -0.23 | 1.123 | 2.15 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 579.8 | 667.2 | 607.5 | 661.8 | 719 | 884 | 1,365 | 1,664 |
| EBITDA | 118.6 | 128.8 | 97.3 | 159.6 | 250.3 | - | - | - |
| EBIT 1 | 86.03 | 46.12 | 125.1 | 183.7 | 158.7 | 168.9 | 775.8 | 900.4 |
| Net income 1 | 53.42 | 60.71 | 1.316 | 73.86 | -38.55 | -13.38 | 65.41 | 124 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 29.16 | 35.67 | 28.94 | 36.16 | 49.70 | 37.88 | 37.88 | 37.88 |
| Nbr of stocks (in thousands) | 53,181 | 54,058 | 54,633 | 55,219 | 57,339 | 58,127 | - | - |
| Announcement Date | 4/13/22 | 2/28/23 | 2/27/24 | 2/25/25 | 2/24/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -164.7x | - | - | -.--% | 2.2B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 9.68x | 6.95x | 18.39x | 1.94% | 394.31B | |
| Weighted average by Cap. | 34.61x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SUPN Stock
- Valuation Supernus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
